Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 1, 2000, Pages 43-47

  Armstrong, William B ^a   Kennedy, Ann R ^b   Wan, X Steven ^b   Atiba, Joshua ^a   McLaren, Christine E ^a   Meyskens Jr , Frank L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOWMAN BIRK INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; LEUKOPLAKIA; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; CHEMOPREVENTION; CHYMOTRYPSIN; ENDOPEPTIDASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 0033980649     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kennedy, A. R. Chemopreventive agents: protease inhibitors. Pharmacol. Ther., 78: 167-209, 1998.
2. Bowman, D. E. Differentiation of soybean antilryptic factors. Proc. Soc. Exp. Biol. Med., 63: 547-550, 1946.
3. Birk, Y. Purification and some properties of a highly active inhibitor of trypsin and α-chymotrypsin from soybeans. Biochim. Biophys. Acta, 54: 191-197, 1961.
4. Odani, S., and Ikenaka, T. J. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitor activity. J. Biochem. (Tokyo), 74: 857-860, 1973.
5. Yavelow, J., Collins, M., Birk, Y., Troll, W., and Kennedy, A. R. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc. Natl. Acad. Sci. USA, 82: 5395-5399, 1985.
6. Kennedy, A. R. The conditions for the modification of radiation transformation in vitro by a tumor promoter and protease inhibitors. Carcinogenesis (Lond.), 6: 1441-1446, 1985.
7. Kennedy, A. R. Prevention of carcinogenesis by protease inhibitors. Cancer Res., 54 (Suppl.): 1999s-2005s, 1994.
8. Billings, P. C., St. Clair, W. H., Maki, P. A., and Kennedy, A. R. Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett., 62: 191-197, 1992.
9. Yavelow, J., Finlay, T. H., Kennedy, A. R., and Troll, W. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res., 43: 2454-2459, 1983.
10. Messina, M., and Barnes, S. The role of soy products in reducing risk of cancer. J. Natl. Cancer Inst., 83: 541-546, 1991.
11. Kennedy, A. R. The evidence for soybean products as cancer preventive agents, J. Nutr., 725: 733s-743s, 1995.
12. Messina, M. J., Persky, V., Setchell, K. D. R., and Barnes, S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21: 113-131, 1994.
13. Tominaga, S. Cancer incidence in Japanese in Japan, Hawaii, and Western United States. J. Natl. Cancer Inst. Monogr., 69: 83-92, 1985.
14. Weed, H., McGandy, R. B., and Kennedy, A. R. Protection against dimethylhydrazine induced adenomatous tumors of the mouse colon by the dietary addition of an extract of soybeans containing the Bowman-Birk protease inhibitor. Carcinogenesis (Lond.), 6: 1239-1241, 1985.
15. St. Clair, W. H., Billings, P. C., Carew, J., Keller-McGandy, C., Newberne, P., and Kennedy, A. R. Suppression of DMH-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res., 50: 580-586, 1990.
16. Billings, P. C., Newberne, P., and Kennedy, A. R. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis (Lond.), 11: 1083-1086, 1990.
17. Messadi, P. V., Billings, P., Schklar, G., and Kennedy, A. R. Inhibition of oral carcinogenesis by a protease inhibitor. J. Natl. Cancer Inst., 76: 447-452, 1986.
18. Kennedy, A. R., Billings, P. C., Maki, P. A., and Newberne, P. Effects of various protease inhibitor preparations on oral carcinogenesis in hamsters induced by 7,12-dimethylbenz(a)anthracene. Nutr. Cancer, 19: 191-200, 1993.
19. Witschi, H., and Kennedy, A. R. Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor. Carcinogenesis (Lond.), 10: 2275-2277, 1989.
20. Evans, S. M., Szuhaj, B. F., Van Winkle, T., Michel, K., and Kennedy, A. R. Protection against metastasis of radiation induced thymic lymphosarcoma and weight loss in C57B1/6NCr1BR mice by an autoclave resistant factor present in soybeans. Radiat. Res., 132: 259-262, 1992.
21. Kennedy, A., and Billings, P. Anticarcinogenic actions of protease inhibitors. In: P. Cerutti, O. Nygaard, and M. Simic (eds.), Anticarcinogenesis and Radiation Protection, pp. 285-295. New York: Plenum Publishing Company, 1987.
22. Kennedy, A. R. Overview: anticarcinogenic activity of protease inhibitors. In: W. Troll and A. R. Kennedy (eds.), Protease Inhibitors as Cancer Chemopreventive Agents, pp. 9-64. New York: Plenum Press, 1993.
23. Kennedy, A. R., Donahue, J. J., and Wan, X. S. Effects of Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum. Nutr. Cancer, 26: 209-217, 1996.
24. von Hofe, E., Newberne, P. M., and Kennedy, A. R. Inhibition of N-nitrosomethylbenzylamine induced esophageal neoplasms by the Bowman-Birk protease inhibitor. Carcinogenesis (Lond.), 12: 2147-2150, 1991.
25. Kennedy, A. R. Cancer prevention by protease inhibitors. Prev. Med., 22: 796-811, 1993.
26. Kennedy, A. R. In vitro studies of anticarcinogenic protease inhibitors. In: W. Troll and A. R. Kennedy (eds.), Protease Inhibitors as Cancer Chemopreventive Agents, pp. 65-91. New York: Plenum Press, 1993.
27. Osborne, T. B., and Mendel, L. B. The use of soybean as food. J. Biol. Chem., 32: 369-387, 1917.
28. Rothman, S. S., and Wells, H. Enhancement of pancreatic enzyme synthesis by pancreozymin. Am. J. Physiol., 213: 215-218, 1967.
29. Mainz, D. L., Black, O., and Webster, P. D. Hormonal control of pancreatic growth. J. Clin. Investig., 52: 2300-2304, 1973.
30. Kennedy, A. R., Szuhaj, B. F., Newberne, P. M., and Billings, P. C. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr. Cancer, 19: 281-302, 1993.
31. Wan, X. S., Koch, C. J., Lord, E. M., Manzone, H., Billings, P. C., Donahue, J. J., Odell, C, S., Miller, J. H., Schmidt, N. A., and Kennedy, A. R. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J. Immunol. Methods, 180: 117-130, 1995.
32. Koch, C. J., and Raleigh, J. A. Radiolytic reduction of protein and nonprotein disulfides in the presence of formate: a chain reaction. Arch. Biochem. Biophys., 287: 75-84, 1991.
33. Haeckel, R. Assay of creatinine in serum, with use of Fuller's earth to remove interferants. Clin. Chem., 27: 179-183, 1981.
34. Meyer, M., Smith, S., and Meyer, R. A., Jr. Creatinine assay by the Fuller's earth procedure or by enzymatic determination is adequate for urine but not plasma of mice. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 106B: 685-689, 1993.
35. Billings, P. C., Carew, J. A., Keller-McGandy, C. E., Goldberg, A., and Kennedy, A. R. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors. Proc. Natl. Acad. Sci. USA, 84: 4801-4805, 1987.
36. Manzone, H., Billings, P. C., Cummings, W. N., Feldman, R., Clark, L. C., Odell, C. S., Horan, A. M., Atiba, J. O., Meyskens, F. L., and Kennedy, A. R. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol. Biomark. Prev., 4: 521-527, 1995.
37. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
38. Siegel, S., and Castellan, N. J. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1988.
39. Kennedy, A. R., and Manzone, H. Effects of protease inhibitors on levels of proteolytic activity in normal and pre-malignant cells and tissues. J. Cell. Biochem., 22 (Suppl.): 188-194, 1995.
40. Wan, X. S., Meyskens, F. L., Armstrong, W. B., Taylor, T. H., and Kennedy, A. R. Relationship between protease activity and Neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk inhibitor. Cancer Epidemiol. Biomark. Prev., 8: 601-608, 1999.
41. Meyskens, F. L., Jr., Armstrong, W. B., Wan, X. S., Taylor, T. H., Jensen, J., Thompson, W., Nguen, Q. A., and Kennedy, A. R. Bowman-Birk inhibitor concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels, and proteolytic activity in buccal mucosal cells. Proc. Am. Assoc. Cancer Res., 40: 432, 1999.